Funding
Funding not disclosed
Founders
Product
Problem
Multi-pass membrane proteins are challenging therapeutic targets due to their complex structure and difficulty in producing stable, functional antibodies against them using conventional methods. This limits the development of antibody-based therapies for diseases where these proteins play a critical role.
Solution
K2 Therapeutics is developing antibody-based therapies by focusing on multi-pass membrane proteins as drug targets. The company employs synthetic biology and directed evolution techniques to overcome the challenges associated with generating antibodies against these complex proteins. This approach allows them to discover and evolve antibodies with high affinity and specificity for multi-pass membrane proteins, potentially unlocking new therapeutic avenues.
Target Audience
The primary target audience includes pharmaceutical companies and researchers focused on developing novel antibody-based therapies for diseases involving multi-pass membrane proteins.
Features
- Antibody discovery platform specifically designed for multi-pass membrane proteins
- Synthetic biology approaches to create diverse antibody libraries
- Directed evolution techniques to optimize antibody affinity and specificity